JP2017509323A5 - - Google Patents

Download PDF

Info

Publication number
JP2017509323A5
JP2017509323A5 JP2016549449A JP2016549449A JP2017509323A5 JP 2017509323 A5 JP2017509323 A5 JP 2017509323A5 JP 2016549449 A JP2016549449 A JP 2016549449A JP 2016549449 A JP2016549449 A JP 2016549449A JP 2017509323 A5 JP2017509323 A5 JP 2017509323A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
binding molecule
molecule according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016549449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017509323A (ja
JP6687526B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/052098 external-priority patent/WO2015114150A1/en
Publication of JP2017509323A publication Critical patent/JP2017509323A/ja
Publication of JP2017509323A5 publication Critical patent/JP2017509323A5/ja
Application granted granted Critical
Publication of JP6687526B2 publication Critical patent/JP6687526B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016549449A 2014-02-02 2015-02-02 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質 Active JP6687526B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461934828P 2014-02-02 2014-02-02
US61/934,828 2014-02-02
PCT/EP2015/052098 WO2015114150A1 (en) 2014-02-02 2015-02-02 Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020065513A Division JP7074792B2 (ja) 2014-02-02 2020-04-01 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質

Publications (3)

Publication Number Publication Date
JP2017509323A JP2017509323A (ja) 2017-04-06
JP2017509323A5 true JP2017509323A5 (enExample) 2018-03-08
JP6687526B2 JP6687526B2 (ja) 2020-04-22

Family

ID=52440681

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016549449A Active JP6687526B2 (ja) 2014-02-02 2015-02-02 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質
JP2020065513A Active JP7074792B2 (ja) 2014-02-02 2020-04-01 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質
JP2022077858A Active JP7520070B2 (ja) 2014-02-02 2022-05-11 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質
JP2024109298A Pending JP2024133644A (ja) 2014-02-02 2024-07-08 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020065513A Active JP7074792B2 (ja) 2014-02-02 2020-04-01 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質
JP2022077858A Active JP7520070B2 (ja) 2014-02-02 2022-05-11 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質
JP2024109298A Pending JP2024133644A (ja) 2014-02-02 2024-07-08 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質

Country Status (21)

Country Link
US (5) US9884911B2 (enExample)
EP (2) EP3696193A1 (enExample)
JP (4) JP6687526B2 (enExample)
KR (1) KR102489452B1 (enExample)
CN (2) CN106459190A (enExample)
AU (3) AU2015212787B2 (enExample)
CA (1) CA2938066C (enExample)
CY (1) CY1123248T1 (enExample)
DK (1) DK3099713T3 (enExample)
ES (1) ES2784238T3 (enExample)
HR (1) HRP20200477T1 (enExample)
HU (1) HUE048478T2 (enExample)
LT (1) LT3099713T (enExample)
MX (1) MX382763B (enExample)
PL (1) PL3099713T3 (enExample)
PT (1) PT3099713T (enExample)
RS (1) RS60156B1 (enExample)
RU (1) RU2678810C2 (enExample)
SI (1) SI3099713T1 (enExample)
SM (1) SMT202000182T1 (enExample)
WO (1) WO2015114150A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3696193A1 (en) * 2014-02-02 2020-08-19 MedImmune Limited Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
MX2020003211A (es) 2017-09-21 2020-09-21 Merck Patent Gmbh Proteina de fusion que comprende una porcion de fgf-18.
WO2021142573A1 (zh) * 2020-01-13 2021-07-22 丁邦 一种融合蛋白及其制法和用途
US20240026036A1 (en) * 2020-09-28 2024-01-25 Medimmune Limited Compounds and methods for treating pain
CN114574444B (zh) * 2020-12-01 2024-05-03 达达生物技术(北京)有限公司 自体纤维母细胞在制备抗类风湿关节炎药物中的应用
TWI821881B (zh) * 2021-01-29 2023-11-11 醫研生物科技有限公司 腫瘤壞死因子α重組抗體及其用途
CN116179667A (zh) * 2022-09-21 2023-05-30 福建中妆技术研究有限公司 基于斑马鱼模型中trpv1信号通路筛选皮肤疼痛舒缓原料的试剂盒及应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DK0939121T4 (da) 1989-09-12 2008-02-04 Ahp Mfg B V TNF-bindende proteiner
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1999033965A1 (en) * 1997-12-24 1999-07-08 Diatech Pty. Ltd. Bifunctional molecules
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
DE19926068C1 (de) * 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
ATE522229T1 (de) 2001-05-30 2011-09-15 Genentech Inc Anti-ngf-antikörper zur behandlung verschiedener erkrankungen
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
ES2357948T3 (es) 2002-10-08 2011-05-04 Rinat Neuroscience Corp. Procedimientos para tratar dolor postquirúrgico mediante la administración de un anticuerpo frente al factor de crecimiento nervioso y composiciones que contienen el mismo.
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
WO2005075514A2 (en) 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
AU2005279347A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
BRPI0606933B8 (pt) 2005-01-24 2021-05-25 Cambridge Antibody Tech Limited membro de ligação específico isolado para fator de crescimento de nervos, molécula de anticorpo isolado, composição e uso de um membro de ligação específico
AU2007257692B2 (en) 2006-06-12 2013-11-14 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
WO2008143954A2 (en) * 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
WO2009092014A1 (en) 2008-01-18 2009-07-23 Gagnon Peter S Enhanced purification of antibodies and antibody fragments by apatite chromatography
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
KR20110031369A (ko) * 2008-07-08 2011-03-25 아보트 러보러터리즈 프로스타글란딘 e2 이원 가변 도메인 면역글로불린 및 이의 용도
JP2011016676A (ja) * 2009-07-07 2011-01-27 Sumitomo Electric Ind Ltd 窒化物半導体基板の製造方法
TW201119676A (en) * 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
KR20140015152A (ko) * 2009-12-02 2014-02-06 악셀레론 파마 인코포레이티드 Fc 융합 단백질의 혈청 반감기를 증가시키는 조성물들 및 방법들
JP2013523153A (ja) * 2010-04-07 2013-06-17 アッヴィ・インコーポレイテッド TNF−α結合タンパク質
ES2704038T3 (es) * 2011-05-24 2019-03-13 Zyngenia Inc Complejos multiespecíficos multivalentes y monovalentes y sus usos
CA2854806A1 (en) 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
EP2915818A3 (en) 2011-12-30 2015-11-11 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
WO2014106001A2 (en) * 2012-12-28 2014-07-03 Abbvie, Inc. Dual specific binding proteins having a receptor sequence
WO2014144299A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST TNFα
EP3696193A1 (en) 2014-02-02 2020-08-19 MedImmune Limited Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
US20210009671A1 (en) 2019-05-10 2021-01-14 Medimmune Limited Compounds and methods for treating pain

Similar Documents

Publication Publication Date Title
JP2017509323A5 (enExample)
CN111518214B (zh) 靶向cldn18.2的双特异性抗体及其制备方法和应用
CA2903595C (en) Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
CN110305210B (zh) 新型抗体分子、其制备方法及其用途
CN107922486B (zh) 异源二聚体多特异性抗体形式
JP2013515508A5 (enExample)
US20170306018A1 (en) Bispecific antibodies against cd3epsilon and ror1
HRP20241775T1 (hr) Bispecifična protutijela koja se specifično vežu na pd1 i lag3
RU2018142544A (ru) Биспецифические связывающие белки и пути их применения
JP2017504578A5 (enExample)
JP2010502183A5 (enExample)
JP2014158485A5 (enExample)
JP2017522891A5 (enExample)
IL295295A (en) Antibodies against fcrl5 and methods of their use
JP2005518789A5 (enExample)
JP2017520575A5 (enExample)
US20210054021A1 (en) Stabilized immunoglobulin domains
JP2019502694A5 (enExample)
JP2020524510A5 (enExample)
JP2020515277A5 (enExample)
JP2019535315A5 (enExample)
JP2020502233A5 (enExample)
JP2021512159A5 (enExample)
JP2017534296A5 (enExample)
RU2016132370A (ru) ХИМЕРНЫЙ БЕЛОК, СОСТАВЛЕННЫЙ ИЗ ДОМЕНА АНТАГОНИСТА NGF И ДОМЕНА АНТАГОНИСТА TNFα